Long-Acting Treatment in Adolescents (LATA)

Phase 3 Unknown 476 enrolled University College, London Africa Health Research Institute · collab Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands. · collab European and Developing Countries Clinical Trials Partnership (EDCTP) · collab Janssen-Cilag Ltd. · collab London School of Hygiene and Tropical Medicine · collab MRC/UVRI and LSHTM Uganda Research Unit · collab PENTA Foundation · collab University of York · collab ViiV Healthcare · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The LATA trial will find out if taking a long-acting injectable form of HIV medicines, called cabotegravir and rilpivirine, every 2 month works as well as taking tablet HIV medicines every day in young people aged 12-19 years of age. The trial is organised by an international group of researchers from Europe and Africa, and will include 460 young people, from Kenya, South Africa, Uganda and Zimbabwe.

Timeline

Start: 2023-06-22
Primary completion: 2025-03
Completion: 2026-03

Outcome

Met primary endpoint

paper Results will be reported in 2026. reads as unknown PMID 41512916 ↗

release “Week 96 results from the LATA trial, led by University College London, showed CAB+RPV LA dosed every two months was superior” reads as met primary endpoint viivhealthcare.com ↗

Publications

Anena D, Chappell E, Nazzinda R, Kiilu C, Chitsamatanga M, Arumugam T, Green A, Kityo Mutuluuza C, Bwakura-Dangarembizi M, Siika A, Archary M, Jafta L, Namukwaya S, Seeley J, Akabwai G, Mugerwa H, Bevers L, Burger D, Walker S, Bamford A, South A, Apoto N, Bush M, Thomason MJ, Spittle B, Ford D, Kekitiinwa AR, Pett SL; LATA Trial Team. Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa. Contemp Clin Trials. 2026 Mar;162:108213. doi: 10.1016/j.cct.2025.108213. Epub 2026 Jan 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cabotegravir	Small molecule	600 mg	Intramuscular
Comparator	Dolutegravir	Other / unclassified	50 mg	Oral
Comparator	Lamivudine	Other / unclassified	300 mg	Oral
Subject	Rilpivirine	Small molecule	900 mg	Intramuscular
Comparator	Tenofovir disoproxil fumarate	Small molecule	245 mg	Oral
Comparator	tenofovir alafenamide	Small molecule	25 mg	Oral